{"disease":{"id":"gaucher-disease-type-1","name":"gaucher disease type 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05253560","title":"Prodromal Parkinsonian Features in GBA1 Mutation Carriers","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT00635427","title":"An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT07223944","title":"A Gaucher Disease Gene Therapy Trial With FLT201","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT00319046","title":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT05447494","title":"Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"CANbridge (Suzhou) Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04055831","title":"Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","has_results":false},{"nct_id":"NCT03950050","title":"Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT03746587","title":"Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"ZevraDenmark","has_results":false},{"nct_id":"NCT00553631","title":"Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04353466","title":"Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT00433147","title":"A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT00430625","title":"A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03333447","title":"Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"CEN Biotech","has_results":false},{"nct_id":"NCT00446550","title":"A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT05487599","title":"A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Prevail Therapeutics","has_results":false},{"nct_id":"NCT04120506","title":"Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT02843035","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT06818838","title":"A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Lingyi Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT00813865","title":"A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT05324943","title":"A Gene Therapy Study in Patients With Gaucher Disease Type 1","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT06050967","title":"A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT00954460","title":"Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Shire","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}